CONTENTS

1 INTRODUCTION AND OBJECTIVES
   Mark Gibson and Siegfried Schmitt
   Purpose of the Book 1
   Technology Transfer and the Drug Discovery and Development Process 5
   Why is Technology Transfer Important? 11
   Scope of the Book 13
   References 18
   About the Authors 20

2 TECHNOLOGY TRANSFER AND KNOWLEDGE MANAGEMENT OVER THE DRUG LIFECYCLE
   Siegfried Schmitt
   Introduction 23
   From Data to Knowledge 25
   Transferring or Sharing Data and Knowledge 26
   Knowledge Sharing Standard Operating Procedure (SOP) 31
   Final Conclusions 32
   References 33
   About the Author 33

www.pda.org/bookstore
5 CHEMICAL DRUG SUBSTANCE DEVELOPMENT AND TECHNOLOGY TRANSFER 97

Alan Harris

Introduction 97

The Drug Substance Development Process 98

Introduction to drug substance process research and development 98

The role of process R&D 100

Good process design 103

The challenge of discontinuous development 108

Barriers to process changes 110

Introduction to Technology Transfer for Drug Substance 111

Aims of Technology Transfer 113

The Impact of Technology Transfer Issues on Process

Development Strategies 114

Early development decisions 114

Route selection, regulatory and sourcing strategies 116

Process freeze 117

Potential Impact of REACH Regulations 118

Applying Risk Analysis and Risk Management to Technology Transfer Decisions 119

Managing the Technology Transfer Programme

Principles for technology transfer 121

The technology transfer team 122

Documentation to be Transferred or Generated During Technology Transfer and Establishment of the Process 123

Success Criteria for Technology Transfer 124

Process Validation 125

Case Study 1: Remacemide Hydrochloride 129

Early process evaluation 129

Process R&D work 131

Early technology transfer of the process for DPAP 131

Second source for DPAP 134

Technology transfer of the final stages of the process 135

Salt selection, polymorphism and particle size 136

Lessons from case study 1 136

Case Study 2: Sibenadet Hydrochloride 138

Synthesis and technology transfer of the benzothiazolone amine intermediate 138

Synthesis and technology transfer of the intermediate benzoate ester 141

Technology transfer of the final steps 141

Control of physical form 143
vi

Crystallisation/drying issues 144
Overall lessons from case study 2 145
Case Study 3: Gefitinib (Iressa®) 147
Overall lessons from case study 3 151
Future Directions for Process Development and the Impact on Technology Transfer 152
Microwave and ultrasonic reactors 152
Micro-reactors technology and continuous processes 153
Chromatographic purification techniques 153
Overall Conclusions 154
References 157
About the Author 160

6 CHEMICAL DRUG PRODUCT DEVELOPMENT AND TECHNOLOGY TRANSFER 161
Mark Gibson
Introduction 161
Product Design 168
Product Optimisation 172
Process Design and Optimisation 177
Process Capability and Robustness 182
Use of PAT to Aid Process Optimisation and Understanding 183
Scale-up and Technology Transfer 187
Process Validation 190
Clinical trials process validation 191
Cleaning validation 192
Process validation of the commercial process — acceptance by production 194
Post-validation and Post-regulatory Approval Changes 200
Documenting the Drug Development Process 203
Chemical (Small Molecules) Drug Product Technology Transfer Case Studies 206
Case study 1: immediate release film coated tablet 206
Case study 2 211
Case study 3: metered dose inhaler 213
References 215
About the Author 218
Contents

7 DRUG SUBSTANCE MANUFACTURING PROCESS DEVELOPMENT AND TECHNOLOGY TRANSFERS — BIOPHARMACEUTICALS 219

Lamine Bouakaz

Introduction 219

Biopharmaceutical Drug Substances 221
   Characteristics of biopharmaceutical drug substances 221
   Biopharmaceutical vs. chemical manufacture 223

Development Phases for Biopharmaceuticals 226
   Pre-clinical program for biopharmaceuticals 226
   Clinical trials program for biopharmaceuticals 229
   Registration of biopharmaceuticals 230
   Commercialization and product lifecycle: Phase IV 231

Development of Biopharmaceutical Drug Substance Manufacturing Processes 232
   Overview of biopharmaceuticals drug substance manufacturing processes 233
   The Quality Target Product Profile 235
   Process development for pre-clinical drug substance manufacture 236
   Process development for Phase I/II biopharmaceutical drug substance manufacture 240
   Phase III biopharmaceutical drug substance manufacturing process development 249
   Process and product characterization studies 260
   Process validation 263
   Registration 266
   Knowledge management 268

Biopharmaceutical Drug Substance Manufacturing Process Technology Transfer from Development to Commercial Scale 268
   Preclinical to Phase I/II manufacturing process technology transfer 269
   Phase I/II to Phase III manufacturing process technology transfer 274

Biopharmaceutical Drug Substance Manufacturing Process Technology Transfer between Commercial Manufacturing Sites 278

References 284

Abbreviations 286

About the Author 288
8 ANALYTICAL METHODOLOGY AND SPECIFICATIONS 289

Mark Hindle

Introduction 289

Method transfer scope 291

Analytical technology transfer: what to do
before formal transfer starts 292

QC involvement during method validation 295

QC involvement post validation 296

Analytical technology transfer: when does it start
and when does it end? 297

Principles of analytical methodology transfer 299

Change control 302

Competition and timing 303

The Technology Transfer Process for Analytical
Methodology and Specifications 303

Stages of analytical method transfer 304

Stage 1: Analytical Strategy 306

Analytical method transfer team 306

Analytical transfer strategy document 309

Stage 2: Knowledge and Information Transfer 313

Information package 314

Knowledge transfer 315

Stage 3: Method Transfer Protocol 320

Testing design 322

Use of statistics 328

Approval of method transfer protocol 330

Stage 4: Analytical Testing 331

Stage 5: Summary Report 333

Transfer approval 333

Post transfer monitoring 334

Post approval changes 334

Method transfer — potential problems
and how to avoid them 335

Summary 345

References 346

About the Author 348

APPENDIX: SPECIAL CONSIDERATIONS FOR TRANSFER OF BIOASSAY METHODS 349

Sharon Longhurst and Ralf Hess

Introduction 349

Cell Based Assays 351
Contents

Issues for Consideration with Respect to Analytical Transfer Strategy 352
  Knowledge and Information Transfer 355
  Method Transfer Protocol 356
  Ligand Binding Assays 358
Issues for Consideration with Respect to Analytical Transfer 359
  Knowledge and Information Transfer 359
  Method Transfer Protocol 361
  References 361
  About the Authors 362

9 TECHNOLOGY TRANSFER, OUTSOURCED ACTIVITIES MANAGEMENT 365
Siegfried Schmitt
Introduction 365
  The purpose of technical/quality agreements 365
  What are technical/quality agreements? 366
Quality Agreements 367
  Applicable regulations
Minimum Requirements for Contents of a Technical/Quality Agreement 371
Key Performance Indicators for Compliance Through Quality Agreements (PQA, premier-research.com) 375
Challenges to Companies in Developing Quality Agreements 377
Summary 377
Examples 378
References 378
About the Author 379

10 AUDITS AND INSPECTIONS 381
Mark Gibson
Introduction 381
The PAI Process 385
Common PAI Deficiencies 390
PAI — What will be Inspected? 392
PAI — How to Prepare? 395
Documented PAI policy 395
Formation of PAI preparation team(s) 396
Documentation, data review and retrieval 399
Product development reports 402
Good level of cGMP and compliance 406
Training and awareness 406
PAI and Launch 408
Technology Transfer: Final Conclusions 409
References 411
About the Author 412

II TRAINING, AN ESSENTIAL ELEMENT OF TECHNOLOGY TRANSFER 415
Siegfried Schmitt
Introduction 415
The Quality by Design Challenge 416
Learning from Technology Transfer 417
Developing a Training Strategy 418
Scope of training 418
Prioritisation and context of training needs 419
Detailed contents of training programmes 420
Methods and tools for delivering training 421
Management of training programmes 422
Trainers 423
Templates and style guidelines 423
Training documentation 424
Language used for training programmes 425
Measuring the Success of Training 425
Auditing of Training 425
Conclusions 426
References 426
About the Author 427

Glossary 429
Index 459